SCHEMBL1334

SCHEMBL1334

COc1ccc(CCC(C)=O)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.72
NPC1 O15118 2/20 0.72
RAB9A P51151 2/20 0.72
KDM4E B2RXH2 1/20 0.72
LMNA P02545 1/20 0.72
TP53 P04637 1/20 0.72
CYP1A2 P05177 1/20 0.72
CYP3A4 P08684 1/20 0.72
MAPT P10636 1/20 0.72
MAOA P21397 1/20 0.72
SLC6A2 P23975 1/20 0.72
SLC6A3 Q01959 1/20 0.72
F2RL1 P55085 1/20 0.70
ALDH1A1 P00352 2/20 0.60
FFAR1 O14842 2/20 0.60
POLB P06746 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
SLC5A1 P13866 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468017 1.00 SMN1; SMN2 (0.72) SMN1; SMN2NPC1RAB9AKDM4ELMNA
Carbon Monoxide SCHEMBL6905879 0.94 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9AKDM4ELMNA
Carbon Monoxide SCHEMBL6904137 0.94 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9AKDM4ELMNA
Benzylacetone SCHEMBL28928562 0.93 ALDH1A1 (0.72) SMN1; SMN2NPC1RAB9AKDM4ELMNA
SCHEMBL11138135 0.91 MAPT (0.62) SMN1; SMN2NPC1RAB9AKDM4ELMNA
SCHEMBL24799818 0.89 F2RL1 (0.72) SMN1; SMN2NPC1RAB9AKDM4ELMNA
SCHEMBL1105476 0.89 ALOX5 (0.68) SMN1; SMN2NPC1RAB9AKDM4ELMNA
SCHEMBL29209947 0.87 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AKDM4ELMNA
SCHEMBL22283502 0.87 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AKDM4ELMNA
SCHEMBL13498520 0.87 ALOX5 (0.61) SMN1; SMN2NPC1RAB9AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873241-B1 AEROSOLISABLE FORMULATION NICOVENTURES TRADING LTD (GB) 2026-05-27 EP claimed
US-12600926-B2 Treatment compositions with modified amino acid dimers for delivering a benefit agent THE PROCTER & GAMBLE COMPANY (US) 2026-04-14 US claimed
EP-4711010-A2 PRO-PERFUME COMPOSITIONS Firmenich SA (CH) 2026-03-18 EP claimed
US-12527344-B2 Aerosolizable formulation Nicoventures Trading Limited (GB) 2026-01-20 US claimed
US-20260000592-A1 TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF PROCTER & GAMBLE (US) 2026-01-01 US claimed
US-12509643-B2 Pro-benefit-agent compounds with carbon/nitrogen bonds THE PROCTER & GAMBLE COMPANY (US) 2025-12-30 US claimed
US-12478090-B2 Aerosolizable formulation Nicoventures Trading Limited (GB) 2025-11-25 US claimed
US-20250302678-A1 ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS PROCTER & GAMBLE (US) 2025-10-02 US claimed
US-12419339-B2 Aerosolized formulation Nicoventures Trading Limited (GB) 2025-09-23 US claimed
EP-4353091-B1 AEROSOLISABLE FORMULATION NICOVENTURES TRADING LTD (GB) 2025-08-06 EP claimed
EP-1210966-A1 Gas filter media with donor and/or acceptor function PAPIERFABRIK SCHOELLER & HOESCH GMBH & CO. KG (DE) 2002-06-05 EP claimed
US-6346402-B1 ACTS ON OPTICALLY ACTIVE (S)-ALPHA-PHENETHYLAMINE AND PYRUVIC ACID TO FORM ACETOPHENONE AND ALANINE; FOR PRODUCING CHEMICAL INTERMEDIATES OF DRUGS AND AGRICULTURAL CHEMICALS KANEKA CORPORATION (JP) 2002-02-12 US claimed
US-6153578-A Fragrance releasing olefinic silanes GENERAL ELECTRIC COMPANY (US) 2000-11-28 US claimed
EP-1045025-A1 (S)-alpha-PHENETHYLAMINE : PYRUVATE TRANSAMINASE KANEKA CORPORATION (JP) 2000-10-18 EP claimed
WO-2000036933-A1 USE OF N-NEOHEXYL-α-ASPARTYL-L-PHENYLALANINE METHYL ESTER AS A FLAVOR MODIFIER THE NUTRASWEET COMPANY (US) 2000-06-29 WO claimed
US-6077923-A CONTAINING GROUPS OF FRAGRANT ESTERS, KETONES, OR ALDEHYDES GENERAL ELECTRIC COMPANY (US) 2000-06-20 US claimed
US-6075111-A A POLYSILOXANE HAVING ONE OR MORE SUBSTITUENTS SELECTED FROM A FRAGRANT ALDEHYDE, KETONE OR ESTER GENERAL ELECTRIC COMPANY (US) 2000-06-13 US claimed
EP-0998911-A2 Fragrance releasing non-volatile polymeric siloxanes GENERAL ELECTRIC COMPANY (US) 2000-05-10 EP claimed
EP-0982313-A2 Fragrance releasing olefinic silanes GENERAL ELECTRIC COMPANY (US) 2000-03-01 EP claimed
US-5944026-A FLAVORED CIGARETTE H.F. & PH.F. REEMTSMA GMBH & CO. (DE) 1999-08-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509643-B2 Pro-benefit-agent compounds with carbon/nitrogen bonds HGFAC, PROKR1, FABP2 SMN1; SMN2 298/4885NPC1 1646/4885RAB9A 3275/4885
US-20260000592-A1 TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF ARGLU1, DAO, PNISR SMN1; SMN2 2825/4885NPC1 4025/4885RAB9A 4009/4885
US-12600926-B2 Treatment compositions with modified amino acid dimers for delivering a benefit agent F2, C9, S100A8 SMN1; SMN2 984/4885NPC1 4560/4885RAB9A 4370/4885
US-12527344-B2 Aerosolizable formulation CHRND, CHRM4, CHRNA9 SMN1; SMN2 1867/4885NPC1 551/4885RAB9A 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.